You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePipecuronium
Accession NumberDB01338
TypeSmall Molecule
GroupsApproved
DescriptionPipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.
Structure
Thumb
Synonyms
Pipecurium
Pipecuronium
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArduanNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pipecuronium bromide
Thumb
  • InChI Key: TXWBOBJCRVVBJF-YTGGZNJNSA-L
  • Monoisotopic Mass: 760.313781786
  • Average Mass: 762.699
DBSALT000367
Categories
UNII1N3O74HM92
CAS number68399-58-6
WeightAverage: 602.8912
Monoisotopic: 602.477106492
Chemical FormulaC35H62N4O4
InChI KeyInChIKey=OWWLUIWOFHMHOQ-XGHATYIMSA-N
InChI
InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
IUPAC Name
4-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-13-(4,4-dimethylpiperazin-4-ium-1-yl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-4-yl]-1,1-dimethylpiperazin-1-ium
SMILES
[H][C@@]12C[C@@H]([[email protected]](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[[email protected]](OC(C)=O)[[email protected]](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androstane-skeleton
  • N-alkylpiperazine
  • N-methylpiperazine
  • Cyclohexylamine
  • Piperazine
  • 1,4-diazinane
  • Acetate salt
  • Quaternary ammonium salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed as a muscle relaxant during anesthesia and surgical procedures.
PharmacodynamicsPipecuronium is a nondepolarizing neuromuscular blocking agent. Neuromuscular blocking agents produce skeletal muscle paralysis by blocking neural transmission at the myoneural junction. The paralysis is selective initially and usually appears in the following muscles consecutively: levator muscles of eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis, and finally, the intercostal muscles and the diaphragm. Neuromuscular blocking agents have no clinically significant effect on consciousness or the pain threshold.
Mechanism of actionNondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeDistribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8906
Blood Brain Barrier+0.6351
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8501
P-glycoprotein inhibitor IInhibitor0.7487
P-glycoprotein inhibitor IIInhibitor0.5983
Renal organic cation transporterNon-inhibitor0.7112
CYP450 2C9 substrateNon-substrate0.8587
CYP450 2D6 substrateNon-substrate0.7823
CYP450 3A4 substrateSubstrate0.7542
CYP450 1A2 substrateNon-inhibitor0.9065
CYP450 2C9 inhibitorNon-inhibitor0.9152
CYP450 2D6 inhibitorNon-inhibitor0.9059
CYP450 2C19 inhibitorNon-inhibitor0.8819
CYP450 3A4 inhibitorNon-inhibitor0.8232
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9438
Ames testNon AMES toxic0.752
CarcinogenicityNon-carcinogens0.9083
BiodegradationNot ready biodegradable0.9272
Rat acute toxicity2.6004 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9193
hERG inhibition (predictor II)Non-inhibitor0.7647
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility9.5e-05 mg/mLALOGPS
logP-1.4ALOGPS
logP-5.3ChemAxon
logS-6.8ALOGPS
pKa (Strongest Basic)5.31ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area59.08 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity193.04 m3·mol-1ChemAxon
Polarizability72.22 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM03AC06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumAclidinium may increase the anticholinergic activities of Pipecuronium.
AclidiniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ambenonium.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pipecuronium.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pipecuronium.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pipecuronium.
BenactyzineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pipecuronium.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pipecuronium.
BezitramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pipecuronium.
Botulinum Toxin Type APipecuronium may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BPipecuronium may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Butorphanol.
CarfentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Carfentanil.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Chlorphenoxamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Pipecuronium.
CimetropiumPipecuronium may increase the anticholinergic activities of Cimetropium.
CodeineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Codeine.
CoumaphosThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Coumaphos.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pipecuronium.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pipecuronium.
DecamethoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipecuronium.
DexetimideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipecuronium.
DihydrocodeineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Donepezil.
DPDPEThe risk or severity of adverse effects can be increased when Pipecuronium is combined with DPDPE.
DronabinolPipecuronium may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Edrophonium.
EluxadolinePipecuronium may increase the constipating activities of Eluxadoline.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pipecuronium.
EthylmorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etorphine.
FentanylThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fentanyl.
FenthionThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fesoterodine.
GalantamineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pipecuronium.
Ginkgo bilobaThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pipecuronium.
GlycopyrroniumPipecuronium may increase the anticholinergic activities of Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pipecuronium.
HydrocodoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pipecuronium.
HydromorphoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pipecuronium.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Pipecuronium.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pipecuronium.
IsoflurophateThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pipecuronium.
KetobemidoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ketobemidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Lofentanil.
MalathionThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipecuronium.
MefloquineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pipecuronium.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Pipecuronium.
MetixeneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Pipecuronium.
MianserinMianserin may increase the anticholinergic activities of Pipecuronium.
MinaprineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mirabegron.
MorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with N-butylscopolammonium bromide.
NabilonePipecuronium may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Neostigmine.
NormethadoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Pipecuronium is combined with NVA237.
OpiumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipecuronium.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipecuronium.
OxycodoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pipecuronium.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pipecuronium.
PentazocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pipecuronium.
PethidineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pethidine.
PhysostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Physostigmine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pipecuronium.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Pipecuronium.
Potassium ChloridePipecuronium may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Pipecuronium.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pipecuronium.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pipecuronium.
PyridostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Pipecuronium.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Pipecuronium.
RamosetronPipecuronium may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Remifentanil.
RivastigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Rivastigmine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Pipecuronium.
SolifenacinThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Solifenacin.
SufentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pipecuronium.
TacrineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tapentadol.
TiotropiumPipecuronium may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Pipecuronium.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pipecuronium.
TopiramateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Pipecuronium.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pipecuronium.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pipecuronium.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pipecuronium.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pipecuronium.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pipecuronium.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Pipecuronium.
UmeclidiniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Vecuronium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786 ]
  3. Kiss JP, Windisch K, Balla A, Sershen H, Lajtha A: Dual effect of DMPP on the resting release of noradrenaline from rat hippocampal slices. Brain Res Bull. 1997;43(3):257-62. [PubMed:9227834 ]
  4. Torocsik A, Oberfrank F, Sershen H, Lajtha A, Nemesy K, Vizi ES: Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus. Eur J Pharmacol. 1991 Sep 24;202(3):297-302. [PubMed:1748153 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786 ]
  2. Zappi L, Song P, Nicosia S, Nicosia F, Rehder K: Do pipecuronium and rocuronium affect human bronchial smooth muscle? Anesthesiology. 1999 Dec;91(6):1616-21. [PubMed:10598601 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Simon G, Biro K, Karpati E, Tuba Z: The effect of the steroid muscle relaxant pipecurium bromide on the acetylcholinesterase activity of red blood cells in vitro. Arzneimittelforschung. 1980;30(2a):360-3. [PubMed:6248079 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:08 / Updated on August 17, 2016 12:23